About The Study: At the lesion level, very intensive lipid-lowering therapy induced substantially greater percent atheroma volume regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion minimum lumen area and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes.
Corresponding Author: To contact the corresponding author, Lorenz Raber, MD, PhD, email lorenz.raeber@insel.ch .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.3200)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the European Society of Cardiology Congress 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.3200?guestAccessKey=1508c832-690b-4b0d-9d00-2a20c1e533dc&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090224
JAMA Cardiology